About Cellectar Biosciences, Inc. - Common Stock (CLRB)
Cellectar Biosc is a biotechnology company focused on the development of innovative cancer therapies. The company specializes in targeted therapies, utilizing its proprietary phospholipid drug conjugate (PDC) platform to create treatments that selectively deliver anti-cancer agents to tumor cells. By enhancing the efficacy and reducing the side effects of conventional cancer treatments, Cellectar aims to improve the outcomes for patients battling various types of cancer. Through ongoing research and clinical trials, the company seeks to advance its pipeline of drug candidates that address unmet medical needs in oncology. Read More
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company’s common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
Synergy CHC Corp. (NASDAQ: SNYR), a provider of consumer health and lifestyle products, most notably “Focusfactor” , today announced a transformative $20 million financing agreement with ACP Agency, LLC , aimed at reducing legacy debt, boosting liquidity, and accelerating the company’s global growth strategy.
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time.
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company’s board of directors has approved the engagement of Oppenheimer & Co. Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process.
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM)
FLORHAM PARK, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming 37th Annual Roth Conference. Details are as follows:
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time.
